摘要
目的参麦注射液联合多西他赛+环磷酰胺(TC)化疗方案对中晚期卵巢癌临床疗效、免疫功能的影响以及不良反应。方法选取辽宁省健康产业集团本钢总医院2018年7月至2019年10月收治的中晚期卵巢癌患者79例作为研究对象,按照用药方案不同分为对照组(37例)和观察组(42例)。对照组给予TC化疗方案,观察组在对照组基础上给予参麦注射液。比较两组患者临床效果、免疫功能和不良反应。结果两组患者治疗有效率比较,差异无统计学意义(P>0.05);观察组稳定率显著高于对照组,差异有统计学意义(P<0.05);治疗后,观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)明显高于对照组,CD8^(+)明显低于对照组,差异有统计学意义(P<0.05);观察组肠道反应、骨髓抑制发生率分别为32.43%、67.57%,明显低于对照组69.05%、83.33%,差异有统计学意义(P<0.05);两组肾功能异常、肝功能异常、心电图改变发生率比较,差异无统计学意义(P>0.05);观察组患者无进展生存期显著长于对照组,差异有统计学意义(P<0.05)。结论参麦注射液与TC化疗方案联合治疗中晚期卵巢癌临床疗效显著,可提高患者机体免疫功能,降低化疗药物的不良反应。
Objective To observe the effect of Shenmai Injection combined with TC chemotherapy regime on clinical efficacy,immune function and adverse reactions of patients with advanced ovarian cancer.Methods A total of 79 patients with advanced ovarian cancer admitted to Benxi Steel General Hospital of China Resources Liaojian Group from July 2018 to October 2019 were selected as the research objects and were divided into a control group and an observation group according to different medication schemes.The control group(n=37)was treated with TC chemotherapy regime,and the observation group(n=42)was treated with Shenmai Injection plus TC chemotherapy regime.The clinical effect,immune function and adverse reactions of the 2 groups were compared.Results There was no significant difference in the effective rate between the 2 groups(P>0.05).The stability rate of the observation group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,CD4^(+),CD3^(+),CD4^(+)/CD8^(+)Of the observation group was significantly higher than the control group,and the differences were statistically significant(P<0.05);the incidence of intestinal reaction and bone marrow suppression in the observation group were 32.43%and 67.57%,which were significantly lower than those in the control group,69.05%and 83.33%.The difference was statistically significant(P<0.05);there was no statistically significant difference in the incidence of abnormal renal function,abnormal liver function,and ECG changes.Conclusion The combination of Shenmai Injection and TC chemotherapy regime in the treatment of advanced ovarian cancer has a significant clinical effect,which can improve the immune function of patients and reduce theadverse reactions of chemotherapy drugs.
作者
施丽
刘璐
宋锐
SHI Li;LIU Lu;SONG Rui(Department of Gynaecology,Benxi Steel General Hospital of China Resources Liaojian Group,Benxi 117022,China)
出处
《中国药物经济学》
2021年第1期85-88,共4页
China Journal of Pharmaceutical Economics
关键词
参麦注射液
TC化疗方案
中晚期
卵巢癌
临床疗效
免疫功能
不良反应
Shenmai injection
TC chemotherapy regimen
Middle and advanced stages
ovarian cancer
Clinical efficacy
Immune function
Adverse reaction
